165 related articles for article (PubMed ID: 12244144)
1. Induction of tumor-reactive CTL by C-side chain variants of the CTL epitope HER-2/neu protooncogene (369-377) selected by molecular modeling of the peptide: HLA-A2 complex.
Castilleja A; Carter D; Efferson CL; Ward NE; Kawano K; Fisk B; Kudelka AP; Gershenson DM; Murray JL; O'Brian CA; Ioannides CG
J Immunol; 2002 Oct; 169(7):3545-54. PubMed ID: 12244144
[TBL] [Abstract][Full Text] [Related]
2. Her-2/ neu altered peptide ligand-induced CTL responses: implications for peptides with increased HLA affinity and T-cell-receptor interaction.
Dionne SO; Myers CE; Smith MH; Lake DF
Cancer Immunol Immunother; 2004 Apr; 53(4):307-14. PubMed ID: 14605764
[TBL] [Abstract][Full Text] [Related]
3. Stimulation of cells from a non-invaded and an invaded lymph node with a HER-2+ tumor with peptides corresponding to T-cell epitopes E75 and G89 induced expansion of central memory cells (TCM) from the metastasis-negative lymph nodes.
Ko BK; Efferson CL; Kawano K; Kuerer HM; Sahin A; Murray JL; Ioannides CG
Int J Oncol; 2004 Jun; 24(6):1413-8. PubMed ID: 15138582
[TBL] [Abstract][Full Text] [Related]
4. Helper peptide G89 (HER-2:777-789) and G89-activated cells regulate the survival of effectors induced by the CTL epitope E75 (HER-2, 369-377). Correlation with the IFN-gamma: IL-10 balance.
Lee TV; Johnston DA; Thomakos N; Honda T; Efferson CL; Ioannides CG
Anticancer Res; 2002; 22(3):1481-90. PubMed ID: 12168827
[TBL] [Abstract][Full Text] [Related]
5. Stimulation of human T cells by an influenza A vector expressing a CTL epitope from the HER-2/neu protooncogene results in higher numbers of antigen-specific TCRhi cells than stimulation with peptide. Divergent roles of IL-2 and IL-15.
Efferson CL; Kawano K; Tsuda N; Palese P; García-Sastre A; Ioannides CG
Anticancer Res; 2005; 25(2A):715-24. PubMed ID: 15868901
[TBL] [Abstract][Full Text] [Related]
6. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.
Fisk B; Blevins TL; Wharton JT; Ioannides CG
J Exp Med; 1995 Jun; 181(6):2109-17. PubMed ID: 7539040
[TBL] [Abstract][Full Text] [Related]
7. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL.
Chen JL; Dunbar PR; Gileadi U; Jäger E; Gnjatic S; Nagata Y; Stockert E; Panicali DL; Chen YT; Knuth A; Old LJ; Cerundolo V
J Immunol; 2000 Jul; 165(2):948-55. PubMed ID: 10878370
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity of undifferentiated, high-TCR density CD8+ cells to methylene groups appended to tumor antigen determines their differentiation or death.
Kawano K; Efferson CL; Peoples GE; Carter D; Tsuda N; Murray JL; Ioannides CG
Cancer Res; 2005 Apr; 65(7):2930-7. PubMed ID: 15805296
[TBL] [Abstract][Full Text] [Related]
9. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes.
Peiper M; Goedegebuure PS; Linehan DC; Ganguly E; Douville CC; Eberlein TJ
Eur J Immunol; 1997 May; 27(5):1115-23. PubMed ID: 9174600
[TBL] [Abstract][Full Text] [Related]
10. Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity.
Keogh E; Fikes J; Southwood S; Celis E; Chesnut R; Sette A
J Immunol; 2001 Jul; 167(2):787-96. PubMed ID: 11441084
[TBL] [Abstract][Full Text] [Related]
11. Identification of activated tumor antigen-reactive CD8+ cells in healthy individuals.
Lee TV; Anderson BW; Peoples GE; Castilleja A; Murray JL; Gershenson DM; Ioannides CG
Oncol Rep; 2000; 7(3):455-66. PubMed ID: 10767352
[TBL] [Abstract][Full Text] [Related]
12. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer.
Murray JL; Gillogly ME; Przepiorka D; Brewer H; Ibrahim NK; Booser DJ; Hortobagyi GN; Kudelka AP; Grabstein KH; Cheever MA; Ioannides CG
Clin Cancer Res; 2002 Nov; 8(11):3407-18. PubMed ID: 12429628
[TBL] [Abstract][Full Text] [Related]
13. MHC recognition by hapten-specific HLA-A2-restricted CD8+ CTL.
Gagnon SJ; Wang Z; Turner R; Damirjian M; Biddison WE
J Immunol; 2003 Sep; 171(5):2233-41. PubMed ID: 12928367
[TBL] [Abstract][Full Text] [Related]
14. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
[TBL] [Abstract][Full Text] [Related]
15. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis.
Jenne L; Arrighi JF; Jonuleit H; Saurat JH; Hauser C
Cancer Res; 2000 Aug; 60(16):4446-52. PubMed ID: 10969791
[TBL] [Abstract][Full Text] [Related]
17. Accelerated HER-2 degradation enhances ovarian tumor recognition by CTL. Implications for tumor immunogenicity.
Castilleja A; Ward NE; O'Brian CA; Swearingen B; Swan E; Gillogly MA; Murray JL; Kudelka AP; Gershenson DM; Ioannides CG
Mol Cell Biochem; 2001 Jan; 217(1-2):21-33. PubMed ID: 11269662
[TBL] [Abstract][Full Text] [Related]
18. A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu-Expressing Tumor in HLA-A2 Transgenic Mice.
Tran T; Diniz MO; Dransart E; Gey A; Merillon N; Lone YC; Godefroy S; Sibley C; Ferreira LC; Medioni J; Oudard S; Johannes L; Tartour E
Clin Cancer Res; 2016 Aug; 22(16):4133-44. PubMed ID: 27006496
[TBL] [Abstract][Full Text] [Related]
19. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
Zaremba S; Barzaga E; Zhu M; Soares N; Tsang KY; Schlom J
Cancer Res; 1997 Oct; 57(20):4570-7. PubMed ID: 9377571
[TBL] [Abstract][Full Text] [Related]
20. Activation of tumor antigen-specific cytotoxic T lymphocytes (CTLs) by human dendritic cells infected with an attenuated influenza A virus expressing a CTL epitope derived from the HER-2/neu proto-oncogene.
Efferson CL; Schickli J; Ko BK; Kawano K; Mouzi S; Palese P; García-Sastre A; Ioannides CG
J Virol; 2003 Jul; 77(13):7411-24. PubMed ID: 12805440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]